Brief: Shenzhen Hepalink Pharmaceutical Says "Heptris" Obtained Approval From Brazilian Health Regulatory Agency
21/04/2021 15:48
April 21 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* "HEPTRIS" OBTAINS APPROVAL FROM BRAZILIAN HEALTH
REGULATORY
AGENCY
Source text for Eikon: ID:nHKSYN4wT
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA